Bevacizumab and Impurities
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Bevacizumab REF: TM-T9904CAS: 216974-75-3 | 95.4% (SEC-HPLC) - CE-SDS:97.5% SEC-HPLC:98.0% | 127.00 €~2,201.00 € | Mon 13 Jan 25 |
 | Bevacizumab (Avastin) REF: 4Z-B-128001CAS: 216974-75-3 | - - - | To inquire | Mon 13 Jan 25 |
Bevacizumab
CAS:216974-75-3
Ipilimumab targets CTLA-4, an immune checkpoint inhibitor. Bevacizumab binds to VEGF-A isoforms.
Purity:
95.4% (SEC-HPLC) - CE-SDS:97.5% SEC-HPLC:98.0%
Color and Shape:
Liquid
Molecular weight:
146.53 kDa
Ref: TM-T9904
| 1mg | 127.00 € | ||
| 2mg | 202.00 € | ||
| 5mg | 374.00 € | ||
| 10mg | 557.00 € | ||
| 25mg | 891.00 € | ||
| 50mg | 1,209.00 € | ||
| 100mg | 1,625.00 € | ||
| 200mg | 2,201.00 € |
Estimated delivery in United States, on Monday 13 Jan 2025
Bevacizumab (Avastin)
CAS:216974-75-3
Formula:
C6638H1016N1720O2108S44
Color and Shape:
White To Off-White Solid
Molecular weight:
149196.82
Ref: 4Z-B-128001
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 13 Jan 2025
